Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
CJC-1295/Ipamorelin: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for CJC-1295/Ipamorelin.
Back to CJC-1295/Ipamorelin overviewData source: Side effect data comes from clinical trials, preclinical research, and anecdotal reports. No FDA-approved labeling exists for this compound.
Reported Side Effects (8 items)
| # | Side Effect |
|---|---|
| 1 | Injection site reactions (10-15%) |
| 2 | Headache (5-10%) |
| 3 | Flushing (rare) |
| 4 | Nausea (rare) |
| 5 | Water retention (theoretical) |
| 6 | Theoretical risk of GH excess: insulin resistance, acromegaly-like effects |
| 7 | Theoretical cancer risk: GH/IGF-1 may promote tumor growth |
| 8 | No long-term safety data (>6 months) exists |